CA2689695A1 - Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals - Google Patents

Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals Download PDF

Info

Publication number
CA2689695A1
CA2689695A1 CA2689695A CA2689695A CA2689695A1 CA 2689695 A1 CA2689695 A1 CA 2689695A1 CA 2689695 A CA2689695 A CA 2689695A CA 2689695 A CA2689695 A CA 2689695A CA 2689695 A1 CA2689695 A1 CA 2689695A1
Authority
CA
Canada
Prior art keywords
human
region
replaced
heavy chain
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2689695A
Other languages
English (en)
French (fr)
Inventor
Janine Schuurman
Tom Vink
Jan Van De Winkel
Aran Frank Labrijn
Paul Parren
Willem Karel Bleeker
Frank Beurskens
Patrick Van Berkel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2689695A1 publication Critical patent/CA2689695A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
CA2689695A 2007-05-31 2008-05-30 Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals Abandoned CA2689695A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700795 2007-05-31
DKPA200700795 2007-05-31
PCT/DK2008/050127 WO2008145140A2 (en) 2007-05-31 2008-05-30 Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals

Publications (1)

Publication Number Publication Date
CA2689695A1 true CA2689695A1 (en) 2008-12-04

Family

ID=39671787

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2689695A Abandoned CA2689695A1 (en) 2007-05-31 2008-05-30 Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals

Country Status (6)

Country Link
US (2) US9322035B2 (enExample)
EP (2) EP2615175B1 (enExample)
JP (1) JP5570974B2 (enExample)
AU (1) AU2008255350B2 (enExample)
CA (1) CA2689695A1 (enExample)
WO (1) WO2008145140A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
WO2008145140A2 (en) 2007-05-31 2008-12-04 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
AU2009324092A1 (en) 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
WO2012064733A2 (en) * 2010-11-09 2012-05-18 Medimmune, Llc Antibody scaffold for homogenous conjugation
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
GB2496375A (en) * 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
US10544220B2 (en) * 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
CN107581155A (zh) * 2017-11-08 2018-01-16 成都新柯力化工科技有限公司 一种用于母猪繁殖的led灯及利用该led灯促进母猪繁殖的方法
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
US20230148574A1 (en) * 2020-04-01 2023-05-18 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd38
MX2022013797A (es) 2020-05-08 2022-11-30 Genmab As Anticuerpos biespecificos contra cd3 y cd20.

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
ES2230848T3 (es) 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2450285C (en) 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
AU2002305478A1 (en) 2001-06-20 2003-01-08 Molecular Staging, Inc. Conjugates of reduced antibodies and biomolecules
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
US20040092719A1 (en) * 2002-09-17 2004-05-13 Eszter Birck-Wilson Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
DK1562972T3 (da) * 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
WO2004042017A2 (en) * 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
AU2005334481A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
EP1810979B1 (en) * 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
TW200732350A (en) * 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
CA2631184A1 (en) * 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US9181344B2 (en) * 2005-12-15 2015-11-10 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
WO2008145140A2 (en) 2007-05-31 2008-12-04 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
JP5511654B2 (ja) * 2007-05-31 2014-06-04 ゲンマブ エー／エス 分子操作により得られた組換え非グリコシル化一価半抗体
EP2152751A1 (en) * 2007-05-31 2010-02-17 Genmab A/S Fusion or linked proteins with extended half life
JP6071165B2 (ja) * 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US20100255012A1 (en) * 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
WO2008145141A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
AU2009324092A1 (en) 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region

Also Published As

Publication number Publication date
US20170037138A1 (en) 2017-02-09
EP2615175B1 (en) 2018-08-08
JP2010527622A (ja) 2010-08-19
AU2008255350A1 (en) 2008-12-04
AU2008255350B2 (en) 2014-07-10
WO2008145140A2 (en) 2008-12-04
US10351629B2 (en) 2019-07-16
US20100306867A1 (en) 2010-12-02
JP5570974B2 (ja) 2014-08-13
US9322035B2 (en) 2016-04-26
EP2167669A2 (en) 2010-03-31
WO2008145140A3 (en) 2009-01-29
EP2615175A1 (en) 2013-07-17

Similar Documents

Publication Publication Date Title
US9322035B2 (en) Recombinant IgG4 monovalent antibodies
US20220396629A1 (en) Recombinant monovalent antibodies and methods for production thereof
AU2008255387B2 (en) Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
US20100291023A1 (en) Method for extending the half-life of exogenous or endogenous soluble molecules
US20100255012A1 (en) Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
AU2017200199B2 (en) Recombinant monovalent antibodies and methods for production thereof
CN101370526B (zh) 重组单价抗体及其制备方法
AU2013216644A1 (en) Recombinant monovalent antibodies and methods for production thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130422

FZDE Dead

Effective date: 20170118